Preclinical studies have also shown that anti-IL-7Rα monoclonal antibodies, including LUSV, delayed T-ALL growth and prolonged mouse survival146–148, which inspired the current trials evaluating the inhibition of IL-7 signaling in T-ALL patients. Here, IL7 is linked to acute lymphoblastic leukemia.